AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8572086 — intervention group
Group type: EXPERIMENTAL
Intervention: Ineraid cochlear implant
Number of subjects: 0
Study 8572086 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical cochleostomy
Number of subjects: 0
Study 8572086 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography and exploratory cochleotomy
Number of subjects: 0
Study 3277608 — intervention group
Group type: EXPERIMENTAL
Intervention: 200,000 IU of vitamin A supplementation
Number of subjects: 25000
Study 3277608 — intervention group
Group type: COMPARATOR
Intervention: Concurrent controls
Number of subjects: 25000
Study 3277608 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical indicators
Number of subjects: 25000
Study 1974399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 2.5 mg
Number of subjects: 7
Study 1974399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg
Number of subjects: 7
Study 1974399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 7
Study 1974399 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 7
Study 1974399 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 20 mg
Number of subjects: 7
Study 1974399 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 40 mg
Number of subjects: 7
Study 1974399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 883006 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron therapy
Number of subjects: 114
Study 883006 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 supplementation
Number of subjects: 114
Study 883006 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 114
Study 31305251 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab
Number of subjects: 0
Study 31305251 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study 28426856 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral voriconazole
Number of subjects: 240
Study 28426856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 26109580 — intervention group
Group type: EXPERIMENTAL
Intervention: Active implicit priming (n = 22) with high-calorie food images paired with negatively valenced images and low-calorie food images paired with positively valenced images.
Number of subjects: 42
Study 26109580 — intervention group
Group type: COMPARATOR
Intervention: Control implicit priming (n = 20) with all food images primed with neutral images.
Number of subjects: 42
Study 26109580 — intervention group
Group type: EXPERIMENTAL
Intervention: Active implicit priming (n = 22)
Number of subjects: 42
Study 24193286 — intervention group
Group type: EXPERIMENTAL
Intervention: PPH
Number of subjects: 122
Study 24193286 — intervention group
Group type: COMPARATOR
Intervention: THD
Number of subjects: 122
Study 21991809 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGMCSF gel
Number of subjects: 58
Study 21991809 — intervention group
Group type: COMPARATOR
Intervention: gel matrix (control group)
Number of subjects: 58
Study 19522050 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 60
Study 19522050 — intervention group
Group type: EXPERIMENTAL
Intervention: Glidescope
Number of subjects: 60
Study 19522050 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath
Number of subjects: 60
Study 19522050 — intervention group
Group type: COMPARATOR
Intervention: Macintosh
Number of subjects: 60
Study 17270384 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor tested (which may be a drug) in case-control studies
Number of subjects: 0
Study 17270384 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure in cohort studies
Number of subjects: 0
Study 17270384 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0
Study 17270384 — intervention group
Group type: COMPARATOR
Intervention: Randomized trials
Number of subjects: 0
Study 16225715 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support ventilation with pressure set at 15 cmH2O (Group 1)
Number of subjects: 35
Study 16225715 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing (Group 2)
Number of subjects: 35
Study 16200777 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of rhTPO at doses of 0.25, 0.5, 1.0, and 2.0 microg/kg
Number of subjects: 34
Study 16200777 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dose of rhTPO at 1.0 microg/kg for 7 - 14 days
Number of subjects: 34
Study 9395007 — intervention group
Group type: EXPERIMENTAL
Intervention: Lodoxamide
Number of subjects: 32
Study 9395007 — intervention group
Group type: COMPARATOR
Intervention: Spaglumic acid
Number of subjects: 32
Study 8204192 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAS cognitive score
Number of subjects: 280
Study 8204192 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental status factor score
Number of subjects: 280
Study 8204192 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal fluency factor score
Number of subjects: 280
Study 8204192 — intervention group
Group type: EXPERIMENTAL
Intervention: Praxis factor score
Number of subjects: 280
Study 2958950 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 40 micrograms three times a day
Number of subjects: 31
Study 2958950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 31691352 — intervention group
Group type: COMPARATOR
Intervention: Water alone
Number of subjects: 100
Study 31691352 — intervention group
Group type: EXPERIMENTAL
Intervention: Water and liquid baby cleanser
Number of subjects: 100
Study 29282650 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported employment intervention
Number of subjects: 283
Study 29282650 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 283
Study 28802593 — intervention group
Group type: EXPERIMENTAL
Intervention: QLB group (posterior quadratus lumborum block with 20mL of 0.375% ropivacaine on each side)
Number of subjects: 70
Study 28802593 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 28802593 — intervention group
Group type: EXPERIMENTAL
Intervention: QLB group
Number of subjects: 70
Study 26291137 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 mcg
Number of subjects: 1039
Study 26291137 — intervention group
Group type: COMPARATOR
Intervention: FF 100 mcg
Number of subjects: 1039
Study 26291137 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI 200/25 mcg
Number of subjects: 1039
Study 23072366 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based sealant
Number of subjects: 276
Study 23072366 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 276
Study 21966478 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term visual deprivation
Number of subjects: 158
Study 21966478 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated testing
Number of subjects: 158
Study 21966478 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender comparison
Number of subjects: 158
Study 18508207 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine
Number of subjects: 68
Study 18508207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 16572425 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing (Hybrid Capture 2)
Number of subjects: 9667
Study 16572425 — intervention group
Group type: COMPARATOR
Intervention: Pap cytology (conventional)
Number of subjects: 9667
Study 16572425 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tests (HPV and Pap)
Number of subjects: 9667
Study 14520777 — intervention group
Group type: EXPERIMENTAL
Intervention: elmex interX medium toothbrush
Number of subjects: 112
Study 14520777 — intervention group
Group type: COMPARATOR
Intervention: ADA‐Accepted flat‐bristle profile toothbrush
Number of subjects: 112
Study 11308437 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow diagrams included in reports of RCTs
Number of subjects: 270
Study 9161310 — intervention group
Group type: EXPERIMENTAL
Intervention: Day hospital treatment
Number of subjects: 179
Study 7838417 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐IFN therapy at a dose of 300,000 UI/die i.m. for 7 days, continuing the same dose on alternate days for 2 weeks
Number of subjects: 10
Study 7838417 — intervention group
Group type: COMPARATOR
Intervention: Control group of 9 patients
Number of subjects: 10
Study 3283097 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin 400 mg single dose
Number of subjects: 200
Study 3283097 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin
Number of subjects: 200
Study 31395418 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 90
Study 31395418 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 90
Study 31395418 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100000 epinephrine
Number of subjects: 90
Study 28549983 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 851
Study 28549983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 851
Study 25863422 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP rise group (334 patients)
Number of subjects: 1097
Study 25863422 — intervention group
Group type: COMPARATOR
Intervention: BNP decrease or no change group (599 patients)
Number of subjects: 1097
Study 25863422 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group (1,097 patients)
Number of subjects: 1097
Study 25863422 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate or severe aortic regurgitation
Number of subjects: 1097
Study 25863422 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in BNP at 30 days
Number of subjects: 1097
Study 25863422 — intervention group
Group type: EXPERIMENTAL
Intervention: Society of Thoracic Surgeons score
Number of subjects: 1097
Study 23906646 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT) administered to the parent
Number of subjects: 35
Study 21538340 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port cholecystectomy (SPC)
Number of subjects: 49
Study 19664250 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment of malaria in infants (IPTi) delivered through the expanded programme of immunization (EPI)
Number of subjects: 1296
Study 19664250 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose infant formulations of IPTi
Number of subjects: 1296
Study 19664250 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer drugs used in IPTi
Number of subjects: 1296
Study 19664250 — intervention group
Group type: COMPARATOR
Intervention: Routine vaccination (EPI)
Number of subjects: 1296
Study 17045409 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram IV infusion (20 mg over 120 min)
Number of subjects: 12
Study 17045409 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 12
Study 16145914 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine diatrizoate with 5‐fluorouracil (5‐FU)
Number of subjects: 160
Study 16145914 — intervention group
Group type: COMPARATOR
Intervention: Contrast medium without 5‐fluorouracil (5‐FU)
Number of subjects: 160
Study 11148810 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol treatment
Number of subjects: 90
Study 11148810 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 90
Study 8765270 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal amnioinfusion
Number of subjects: 79
Study 8765270 — intervention group
Group type: COMPARATOR
Intervention: Control (direct labor induction)
Number of subjects: 79
Study 1577936 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release intrauterine insemination (treatment A)
Number of subjects: 38
Study 1577936 — intervention group
Group type: COMPARATOR
Intervention: Bolus intrauterine insemination (treatment B)
Number of subjects: 38
Study 3899669 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil alone (Group A)
Number of subjects: 30
Study 3899669 — intervention group
Group type: COMPARATOR
Intervention: HCTZ/amiloride (Group B)
Number of subjects: 30
Study 3899669 — intervention group
Group type: COMPARATOR
Intervention: HCTZ and amiloride
Number of subjects: 30
Study 3899669 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil added to HCTZ/amiloride
Number of subjects: 30
Study 3899669 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 30
Study 3899669 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil
Number of subjects: 30
Study 3899669 — intervention group
Group type: EXPERIMENTAL
Intervention: Phases 1 and 2
Number of subjects: 30
Study 3899669 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 2
Number of subjects: 30
Study 30997650 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Sampling Strategy (OSS) using time points of 2, 4, and 8 hours post-dose for first-line anti-TB drugs (isoniazid, rifampicin, ethambutol, pyrazinamide)
Number of subjects: 0
Study 30997650 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation of OSS
Number of subjects: 0
Study 29266340 — intervention group
Group type: EXPERIMENTAL
Intervention: Advisory brochure on fish consumption guidelines
Number of subjects: 0
Study 26891645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates sessions in addition to conventional treatment with occlusal splint
Number of subjects: 40
Study 26891645 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with occlusal splint
Number of subjects: 40
Study 24962042 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 4 screws and a 4‐hole miniplate for internal fixation
Number of subjects: 30
Study 24962042 — intervention group
Group type: COMPARATOR
Intervention: Group B: 3 screws (only 1 screw in the proximal segment) and a 4‐hole miniplate
Number of subjects: 30
Study 24962042 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 24962042 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A and Group B
Number of subjects: 30
Study 22437411 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hemoglobin (13-15 g/dl)
Number of subjects: 1265
Study 22437411 — intervention group
Group type: COMPARATOR
Intervention: Lower hemoglobin (9-11 g/dl)
Number of subjects: 1265
Study 20103685 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 527
Study 18271233 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) warming therapy combined with oral administration of Pyridostigmine (90 ‐ 240 mg each day) and Prednisone (30 ‐ 60 mg each day)
Number of subjects: 60
Study 18271233 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Pyridostigmine (240‐480 mg each day) and Prednisone (60‐100 mg each day)
Number of subjects: 60
Study 16279900 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG IFN alpha‐2b 1.5 microg/kg per wk plus RBV 800 mg per day (Regimen A)
Number of subjects: 321
Study 16279900 — intervention group
Group type: COMPARATOR
Intervention: PEG IFN alpha‐2b 1.0 microg/kg per wk plus RBV 1,000‐1,200 mg per day (Regimen B)
Number of subjects: 321
Study 16279900 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy nonresponders
Number of subjects: 321
Study 16279900 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN monotherapy nonresponders
Number of subjects: 321
Study 16279900 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy relapsers
Number of subjects: 321
Study 16279900 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV ribonucleic acid levels <100,000 copies/mL
Number of subjects: 321
Study 16279900 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype 1 patients
Number of subjects: 321
Study 16279900 — intervention group
Group type: EXPERIMENTAL
Intervention: African Americans
Number of subjects: 321
Study 11872551 — intervention group
Group type: EXPERIMENTAL
Intervention: Homoeopathic immunotherapy
Number of subjects: 242
Study 11872551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 10195529 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of bupivacaine 0.25%
Number of subjects: 50
Study 10195529 — intervention group
Group type: COMPARATOR
Intervention: 10 mL of saline
Number of subjects: 50
Study 10195529 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL of bupivacaine 0.5%
Number of subjects: 50
Study 10195529 — intervention group
Group type: COMPARATOR
Intervention: 5 mL of saline
Number of subjects: 50
Study 10195529 — intervention group
Group type: COMPARATOR
Intervention: No epidural top-up
Number of subjects: 50
Study 9626172 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (3 g TID for 6 months)
Number of subjects: 26
Study 9626172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 1770314 — intervention group
Group type: EXPERIMENTAL
Intervention: D-alpha-tocopherol (vitamin E) supplementation at dosages of 150, 225, 800, or 1200 IU for 21 days
Number of subjects: 12
Study 1770314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6126441 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg diacetolol
Number of subjects: 6
Study 6126441 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg diacetolol
Number of subjects: 6
Study 6126441 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg diacetolol
Number of subjects: 6
Study 6126441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30987457 — intervention group
Group type: EXPERIMENTAL
Intervention: BOOSTTM midsole materials
Number of subjects: 0
Study 30987457 — intervention group
Group type: COMPARATOR
Intervention: Conventional materials
Number of subjects: 0
Study 30233159 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (500 mg/day) with meloxicam (Mlx)
Number of subjects: 110
Study 30233159 — intervention group
Group type: COMPARATOR
Intervention: Meloxicam (Mlx) alone
Number of subjects: 110
Study 26818756 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle vibration treatment at 200 Hz
Number of subjects: 48
Study 26818756 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle vibration treatment at 100 Hz
Number of subjects: 48
Study 26818756 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 48
Study 24818764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 24818764 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dosage EPA-E (1800 mg/d)
Number of subjects: 243
Study 24818764 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosage EPA-E (2700 mg/d)
Number of subjects: 243
Study 22639399 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program (1 hour twice a week)
Number of subjects: 60
Study 22639399 — intervention group
Group type: COMPARATOR
Intervention: Counseling on the risk of diabetes and its prevention
Number of subjects: 60
Study 20137766 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl pectin (FPNS)
Number of subjects: 18
Study 20137766 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl chitosan (FChNS)
Number of subjects: 18
Study 20137766 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl in chitosan-poloxamer 188 (FChPNS)
Number of subjects: 18
Study 20137766 — intervention group
Group type: COMPARATOR
Intervention: Oral transmucosal fentanyl citrate (OTFC)
Number of subjects: 18
Study 18613959 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year group behavioral program based on Self-Determination Theory (SDT) with 30 sessions of 2 hours each, delivered weekly or bi-weekly.
Number of subjects: 0
Study 18613959 — intervention group
Group type: COMPARATOR
Intervention: General health education curriculum.
Number of subjects: 0
Study 15966958 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive outreach
Number of subjects: 30
Study 15966958 — intervention group
Group type: COMPARATOR
Intervention: Standard community care
Number of subjects: 30
Study 11818200 — intervention group
Group type: EXPERIMENTAL
Intervention: CEF14 (chemotherapy every 14 days)
Number of subjects: 392
Study 11818200 — intervention group
Group type: COMPARATOR
Intervention: CEF21 (chemotherapy every 21 days)
Number of subjects: 392
Study 11818200 — intervention group
Group type: EXPERIMENTAL
Intervention: CEF14
Number of subjects: 392
Study 11818200 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 392
Study 9880419 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-gentamicin implant plus metronidazole 20 to 40 mg/kg/day IV for 7 days
Number of subjects: 73
Study 9880419 — intervention group
Group type: COMPARATOR
Intervention: Open wounds treated with local cleansing, metronidazole 20 to 40 mg/kg/day IV and gentamicin 5 mg/kg/day IV for 7 days
Number of subjects: 73
Study 7722116 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory training program
Number of subjects: 22
Study 2024227 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin and clavulanate
Number of subjects: 0
Study 2024227 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin, gentamicin and clindamycin (standard therapy)
Number of subjects: 0
Study 7270476 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting (skipping breakfast)
Number of subjects: 0
Study 31561651 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anesthesia without sedation
Number of subjects: 57
Study 31561651 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 57
Study 27179664 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive sacroiliac joint fusion (SIJF) using triangular titanium implants
Number of subjects: 103
Study 27179664 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (CM)
Number of subjects: 103
Study 25470476 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery group (n = 30)
Number of subjects: 60
Study 25470476 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 60
Study 23339538 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 153
Study 23339538 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure with Cognitive Restructuring (PE/CR)
Number of subjects: 153
Study 21366805 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily for 8 weeks
Number of subjects: 47